Epidemiology of the Antiphospholipid Syndrome

Laura Durcan, Michelle Petri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Antiphospholipid antibodies (aPL) are implicated in approximately a quarter of a million thrombotic events in the United States annually. These antibodies, anticardiolipin, anti-β2 glycoprotein I, and the lupus anticoagulant, can be found in healthy subjects with an increased prevalence in older populations, in children, in infections, and with malignancies. The risk of thrombosis is highest with multiple high-titre antibodies and in those in whom the lupus anticoagulant is detected. Factors such as hypertension and smoking also contribute to the rate of thrombosis. In patients with systemic lupus erythematosus (SLE), the lupus anticoagulant is the strongest predictor of thrombosis, with a 50% 20-year risk. The most common manifestation of antiphospholipid syndrome is deep venous thrombosis. Stroke is the most common arterial event, and aPL are implicated most frequently in those under the age of 50. There are conflicting data regarding pregnancy morbidity and aPL. Whilst pregnancy loss appears to occur at a higher rate with aPL, the data on other pregnancy morbidity, such as preeclampsia and the HELLP syndrome, have not consistently shown an association. In SLE, aPL are common, with the prevalence of anticardiolipin antibodies being 46% and that of the lupus anticoagulant 26%. Thus, aPL occur at a low frequency in the general population and are implicated in many thrombotic events. The risk of thrombosis increases with the antibody titre, number and presence of the lupus anticoagulant, which is of particular importance in the prediction of thrombosis in SLE.

Original languageEnglish (US)
Title of host publicationHandbook of Systemic Autoimmune Diseases
PublisherElsevier Ltd
Pages17-30
Number of pages14
Volume12
DOIs
StatePublished - 2016

Publication series

NameHandbook of Systemic Autoimmune Diseases
Volume12
ISSN (Print)15715078

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Lupus Coagulation Inhibitor
Epidemiology
Thrombosis
Systemic Lupus Erythematosus
Anticardiolipin Antibodies
Pregnancy
HELLP Syndrome
Morbidity
Antibodies
Pre-Eclampsia
Venous Thrombosis
Population
Anti-Idiotypic Antibodies
Glycoproteins
Healthy Volunteers
Smoking
Stroke
Hypertension

Keywords

  • Antiphospholipid antibodies
  • epidemiology
  • thrombosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Endocrinology, Diabetes and Metabolism

Cite this

Durcan, L., & Petri, M. (2016). Epidemiology of the Antiphospholipid Syndrome. In Handbook of Systemic Autoimmune Diseases (Vol. 12, pp. 17-30). (Handbook of Systemic Autoimmune Diseases; Vol. 12). Elsevier Ltd. https://doi.org/10.1016/B978-0-444-63655-3.00002-8

Epidemiology of the Antiphospholipid Syndrome. / Durcan, Laura; Petri, Michelle.

Handbook of Systemic Autoimmune Diseases. Vol. 12 Elsevier Ltd, 2016. p. 17-30 (Handbook of Systemic Autoimmune Diseases; Vol. 12).

Research output: Chapter in Book/Report/Conference proceedingChapter

Durcan, L & Petri, M 2016, Epidemiology of the Antiphospholipid Syndrome. in Handbook of Systemic Autoimmune Diseases. vol. 12, Handbook of Systemic Autoimmune Diseases, vol. 12, Elsevier Ltd, pp. 17-30. https://doi.org/10.1016/B978-0-444-63655-3.00002-8
Durcan L, Petri M. Epidemiology of the Antiphospholipid Syndrome. In Handbook of Systemic Autoimmune Diseases. Vol. 12. Elsevier Ltd. 2016. p. 17-30. (Handbook of Systemic Autoimmune Diseases). https://doi.org/10.1016/B978-0-444-63655-3.00002-8
Durcan, Laura ; Petri, Michelle. / Epidemiology of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases. Vol. 12 Elsevier Ltd, 2016. pp. 17-30 (Handbook of Systemic Autoimmune Diseases).
@inbook{f0ccf8ef8b8b42929df74da5bc5ec95d,
title = "Epidemiology of the Antiphospholipid Syndrome",
abstract = "Antiphospholipid antibodies (aPL) are implicated in approximately a quarter of a million thrombotic events in the United States annually. These antibodies, anticardiolipin, anti-β2 glycoprotein I, and the lupus anticoagulant, can be found in healthy subjects with an increased prevalence in older populations, in children, in infections, and with malignancies. The risk of thrombosis is highest with multiple high-titre antibodies and in those in whom the lupus anticoagulant is detected. Factors such as hypertension and smoking also contribute to the rate of thrombosis. In patients with systemic lupus erythematosus (SLE), the lupus anticoagulant is the strongest predictor of thrombosis, with a 50{\%} 20-year risk. The most common manifestation of antiphospholipid syndrome is deep venous thrombosis. Stroke is the most common arterial event, and aPL are implicated most frequently in those under the age of 50. There are conflicting data regarding pregnancy morbidity and aPL. Whilst pregnancy loss appears to occur at a higher rate with aPL, the data on other pregnancy morbidity, such as preeclampsia and the HELLP syndrome, have not consistently shown an association. In SLE, aPL are common, with the prevalence of anticardiolipin antibodies being 46{\%} and that of the lupus anticoagulant 26{\%}. Thus, aPL occur at a low frequency in the general population and are implicated in many thrombotic events. The risk of thrombosis increases with the antibody titre, number and presence of the lupus anticoagulant, which is of particular importance in the prediction of thrombosis in SLE.",
keywords = "Antiphospholipid antibodies, epidemiology, thrombosis",
author = "Laura Durcan and Michelle Petri",
year = "2016",
doi = "10.1016/B978-0-444-63655-3.00002-8",
language = "English (US)",
volume = "12",
series = "Handbook of Systemic Autoimmune Diseases",
publisher = "Elsevier Ltd",
pages = "17--30",
booktitle = "Handbook of Systemic Autoimmune Diseases",

}

TY - CHAP

T1 - Epidemiology of the Antiphospholipid Syndrome

AU - Durcan, Laura

AU - Petri, Michelle

PY - 2016

Y1 - 2016

N2 - Antiphospholipid antibodies (aPL) are implicated in approximately a quarter of a million thrombotic events in the United States annually. These antibodies, anticardiolipin, anti-β2 glycoprotein I, and the lupus anticoagulant, can be found in healthy subjects with an increased prevalence in older populations, in children, in infections, and with malignancies. The risk of thrombosis is highest with multiple high-titre antibodies and in those in whom the lupus anticoagulant is detected. Factors such as hypertension and smoking also contribute to the rate of thrombosis. In patients with systemic lupus erythematosus (SLE), the lupus anticoagulant is the strongest predictor of thrombosis, with a 50% 20-year risk. The most common manifestation of antiphospholipid syndrome is deep venous thrombosis. Stroke is the most common arterial event, and aPL are implicated most frequently in those under the age of 50. There are conflicting data regarding pregnancy morbidity and aPL. Whilst pregnancy loss appears to occur at a higher rate with aPL, the data on other pregnancy morbidity, such as preeclampsia and the HELLP syndrome, have not consistently shown an association. In SLE, aPL are common, with the prevalence of anticardiolipin antibodies being 46% and that of the lupus anticoagulant 26%. Thus, aPL occur at a low frequency in the general population and are implicated in many thrombotic events. The risk of thrombosis increases with the antibody titre, number and presence of the lupus anticoagulant, which is of particular importance in the prediction of thrombosis in SLE.

AB - Antiphospholipid antibodies (aPL) are implicated in approximately a quarter of a million thrombotic events in the United States annually. These antibodies, anticardiolipin, anti-β2 glycoprotein I, and the lupus anticoagulant, can be found in healthy subjects with an increased prevalence in older populations, in children, in infections, and with malignancies. The risk of thrombosis is highest with multiple high-titre antibodies and in those in whom the lupus anticoagulant is detected. Factors such as hypertension and smoking also contribute to the rate of thrombosis. In patients with systemic lupus erythematosus (SLE), the lupus anticoagulant is the strongest predictor of thrombosis, with a 50% 20-year risk. The most common manifestation of antiphospholipid syndrome is deep venous thrombosis. Stroke is the most common arterial event, and aPL are implicated most frequently in those under the age of 50. There are conflicting data regarding pregnancy morbidity and aPL. Whilst pregnancy loss appears to occur at a higher rate with aPL, the data on other pregnancy morbidity, such as preeclampsia and the HELLP syndrome, have not consistently shown an association. In SLE, aPL are common, with the prevalence of anticardiolipin antibodies being 46% and that of the lupus anticoagulant 26%. Thus, aPL occur at a low frequency in the general population and are implicated in many thrombotic events. The risk of thrombosis increases with the antibody titre, number and presence of the lupus anticoagulant, which is of particular importance in the prediction of thrombosis in SLE.

KW - Antiphospholipid antibodies

KW - epidemiology

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85016788762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016788762&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63655-3.00002-8

DO - 10.1016/B978-0-444-63655-3.00002-8

M3 - Chapter

VL - 12

T3 - Handbook of Systemic Autoimmune Diseases

SP - 17

EP - 30

BT - Handbook of Systemic Autoimmune Diseases

PB - Elsevier Ltd

ER -